CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, M...
Phase 1
Pittsburgh, Pennsylvania, United States
ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph ...
Phase 2
Pittsburgh, Pennsylvania, United States and 9 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Pittsburgh, Pennsylvania, United States and 32 other locations
therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 2, Phase 3
Pittsburgh, Pennsylvania, United States and 70 other locations
Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetini...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States
This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) vir...
Early Phase 1
Pittsburgh, Pennsylvania, United States
This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or IV melanoma who have progressed on prior anti-...
Phase 2
Pittsburgh, Pennsylvania, United States
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investiga...
Phase 2
Pittsburgh, Pennsylvania, United States and 55 other locations
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...
Phase 2
Pittsburgh, Pennsylvania, United States and 56 other locations
A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomark...
Phase 2
Pittsburgh, Pennsylvania, United States
Clinical trials
Research sites
Resources
Legal